Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Helix BioPharma Corp.
HBPHelix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada. Address: 1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3
Analytics
Precio Objetivo de WallStreet
3.49 CADRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave HBP
Análisis de dividendos HBP
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout HBP
Valoración de la acción HBP
Finanzas HBP
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |